Fresenius Kabi

Formycon AG has entered into a distribution agreement with Teva's subsidiary Ratiopharm for the semi-exclusive commercialization of its Stelara biosimilar FYB202, branded as Fymskina, in Germany.

Fresenius Kabi Canada launched Iodixanol Injection 270 and 320, marking the first generic injectable iodinated contrast media available in the Canadian market.

mAbxience has signed two strategic licensing agreements to commercialize biosimilar candidates across Italy and Southeast Europe, partnering with Abiogen Pharma and Corapharm respectively.

Fresenius Kabi has commercially launched Tyenne®, the first and only tocilizumab biosimilar available in Canada, offered in both subcutaneous and intravenous formulations.

Fresenius Kabi has introduced Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials in the United States, expanding its emergency medicine portfolio.

The global smart drug delivery systems market reached $12 billion in 2024 and is projected to grow at a CAGR of 17% through 2034, driven by rising chronic disease prevalence and technological advancements.

Pacira BioSciences has reached a settlement with Fresenius Kabi and other companies regarding patent litigation for its non-opioid pain therapy EXPAREL, allowing limited generic entry beginning in early 2030.

Amgen and Fresenius Kabi have settled their BPCIA litigation regarding Fresenius's denosumab biosimilar FKS518, with the New Jersey District Court entering a dismissal order on March 7, 2025.

Health Canada approved Otulfi, a ustekinumab biosimilar, for subcutaneous and intravenous use in treating Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis.

Formycon's biosimilar candidate FYB206, referencing Keytruda, has commenced its clinical development program, including Phase I and Phase III studies, marking a significant milestone.